Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.70 |
| ▸ | MAOB | P27338 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TTR | P02766 | 2/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.59 |
| ▸ | CTSL | P07711 | 3/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 4/20 | 0.57 |
| ▸ | BCHE | P06276 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472764 | 1.00 | FDPS (0.70) | FDPSMAOBHPGDTTRDPP4 | |
| SCHEMBL17301814 | 0.89 | MAOB (0.73) | FDPSMAOBTTRDPP4ACHE | |
| SCHEMBL8046251 | 0.87 | FDPS (0.84) | FDPSMAOBHPGDTTRDPP4 | |
| SCHEMBL28859349 | 0.87 | FDPS (0.84) | FDPSMAOBHPGDTTRDPP4 | |
| SCHEMBL8046247 | 0.87 | FDPS (0.84) | FDPSMAOBHPGDTTRDPP4 | |
| SCHEMBL31087309 | 0.87 | FDPS (0.84) | FDPSMAOBHPGDTTRDPP4 | |
| SCHEMBL28859350 | 0.87 | FDPS (0.84) | FDPSMAOBHPGDTTRDPP4 | |
| SCHEMBL6477187 | 0.87 | FDPS (0.60) | FDPSMAOBHPGDTTRDPP4 | |
| SCHEMBL6477190 | 0.87 | FDPS (0.60) | FDPSMAOBHPGDTTRDPP4 | |
| SCHEMBL14816553 | 0.86 | TTR (0.57) | FDPSMAOBHPGDTTRDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| WO-2018144620-A9 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD. (AU) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018144620-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-RE42700-E1 | Induction of apoptosis in cancer cells | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-13 | — | — | US | disclosed |
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-05-13 | — | — | US | disclosed |
| US-6632963-B1 | Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | FDPS 629/4885MAOB 3192/4885HPGD 553/4885 |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | AHR, TYR, MC1R | FDPS 3696/4885MAOB 166/4885HPGD 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.